18.46
0.66%
0.155
Corbus Pharmaceuticals Holdings Inc stock is traded at $18.46, with a volume of 154.82K.
It is up +0.66% in the last 24 hours and down -4.06% over the past month.
Corbus Pharmaceuticals Holdings Inc is a precision oncology company with a diversified portfolio and is committed to helping people defeat serious illness by bringing scientific approaches to well-understood biological pathways. The company's development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity.
See More
Previous Close:
$18.31
Open:
$18.43
24h Volume:
154.82K
Relative Volume:
0.24
Market Cap:
$226.61M
Revenue:
$1.54M
Net Income/Loss:
$-34.97M
P/E Ratio:
-1.6786
EPS:
-11
Net Cash Flow:
$-30.09M
1W Performance:
+13.77%
1M Performance:
-4.06%
6M Performance:
-52.46%
1Y Performance:
+252.39%
Corbus Pharmaceuticals Holdings Inc Stock (CRBP) Company Profile
Name
Corbus Pharmaceuticals Holdings Inc
Sector
Industry
Phone
617-963-0103
Address
500 RIVER RIDGE DRIVE, NORWOOD, MA
Corbus Pharmaceuticals Holdings Inc Stock (CRBP) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Sep-08-20 | Downgrade | BTIG Research | Buy → Neutral |
Sep-08-20 | Downgrade | Jefferies | Buy → Hold |
Sep-08-20 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
Sep-08-20 | Downgrade | ROTH Capital | Buy → Neutral |
Jul-07-20 | Initiated | ROTH Capital | Buy |
Jun-17-20 | Initiated | BTIG Research | Buy |
Mar-26-20 | Initiated | Nomura | Buy |
Apr-05-19 | Initiated | Jefferies | Buy |
Mar-20-19 | Initiated | Oppenheimer | Outperform |
Jan-11-19 | Reiterated | Cantor Fitzgerald | Overweight |
Dec-26-18 | Initiated | H.C. Wainwright | Buy |
Dec-07-18 | Initiated | RBC Capital Mkts | Outperform |
Oct-24-18 | Initiated | B. Riley FBR | Buy |
Jan-19-18 | Initiated | Raymond James | Outperform |
Dec-14-17 | Reiterated | Cantor Fitzgerald | Overweight |
Nov-08-17 | Reiterated | Noble Financial | Buy |
Sep-29-17 | Resumed | Noble Financial | Buy |
Mar-30-17 | Reiterated | Cantor Fitzgerald | Overweight |
Nov-15-16 | Reiterated | JMP Securities | Mkt Outperform |
Nov-11-16 | Reiterated | Noble Financial | Buy |
View All
Corbus Pharmaceuticals Holdings Inc Stock (CRBP) Latest News
Vanguard Group Inc's Strategic Acquisition in Corbus Pharmaceuti - GuruFocus.com
Corbus Pharmaceuticals' (CRBP) Outperform Rating Reaffirmed at Wedbush - MarketBeat
Corbus Pharmaceuticals Presents New CRB-913 Pre-Clinical Data At Obesity Week 2024 - GlobeNewswire
Corbus Pharmaceuticals Holdings Inc. stock outperforms competitors on strong trading day - MarketWatch
Corbus Pharmaceuticals Holdings Inc. stock underperforms Thursday when compared to competitors - MarketWatch
Short Interest in Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) Grows By 5.8% - MarketBeat
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) Receives $65.86 Consensus Price Target from Brokerages - MarketBeat
Corbus Pharmaceuticals Holdings Inc. stock outperforms competitors despite losses on the day - MarketWatch
Corbus Pharmaceuticals to Present at the Guggenheim Securities Healthcare Innovation Conference - GlobeNewswire
Corbus Pharmaceuticals Holdings Inc. stock rises Monday, still underperforms market - MarketWatch
(CRBP) Investment Report - Stock Traders Daily
Corbus Pharmaceuticals Holdings Inc. stock underperforms Friday when compared to competitors - MarketWatch
Corbus Pharmaceuticals Holdings Inc. stock rises Thursday, still underperforms market - MarketWatch
Corbus Pharmaceuticals Holdings Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
Corbus Pharmaceuticals Holdings Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
Corbus Pharmaceuticals (NASDAQ:CRBP) Stock Price Crosses Below 50 Day Moving AverageWhat's Next? - MarketBeat
Oppenheimer maintains steady target on Corbus Pharmaceuticals By Investing.com - Investing.com UK
Corbus Pharmaceuticals Holdings Inc. stock underperforms Wednesday when compared to competitors despite daily gains - MarketWatch
Corbus Announces Enrollment Completion of Dose Escalation Stage of Phase 1 Clinical Trial of Its Next Generation Nectin-4 Targeting ADC (CRB-701) - GlobeNewswire
Millennium Management LLC Adjusts Stake in Corbus Pharmaceuticals - GuruFocus.com
Corbus Pharmaceuticals Holdings Inc. stock underperforms Monday when compared to competitors - MarketWatch
Octagon Capital Advisors LP Increases Stake in Corbus Pharmaceuticals Holdings Inc - GuruFocus.com
Short Interest in Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) Rises By 106.3% - MarketBeat
Short Interest in Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) Grows By 106.3% - MarketBeat
Buying Buzz: Corbus Pharmaceuticals Holdings Inc [CRBP] 10% Owner Cormorant Asset Management, LP purchases 350,000 shares of the company – Knox Daily - Knox Daily
Vertex Pharmaceuticals, Inc. [NASDAQ: VRTX] Sees Increase in Stock Value - Knox Daily
Stock Surge: Corbus Pharmaceuticals Holdings Inc (CRBP) Closes at 18.52, Marking a -5.41 Increase/Decrease - The Dwinnex
Corbus Pharmaceuticals Holdings Inc’s Shares Reel: -65.28% Quarterly Revenue Decline Amid 222.98M Market Cap - The InvestChronicle
Millennium Management LLC Sells 83,253 Shares of Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) - MarketBeat
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) Receives Average Rating of "Buy" from Analysts - MarketBeat
10% Owner Cormorant Asset Management, LP acquired 350,000 shares of Corbus Pharmaceuticals Holdings Inc [CRBP] – Knox Daily - Knox Daily
Is Corbus Pharmaceuticals Holdings, Inc. (CRBP) the Best Russell 2000 Stock to Buy According to Analysts? - Insider Monkey
Corbus Pharmaceuticals Holdings Inc’s Market Journey: Closing Weak at 19.23, Down -6.79 - The Dwinnex
Point72 Asset Management L.P. Reduces Stock Holdings in Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) - Defense World
Corbus Pharmaceuticals Holdings Inc (CRBP) is looking forward to a strong quarter - SETE News
Point72 Asset Management L.P. Reduces Position in Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) - MarketBeat
Corbus Pharmaceuticals Holdings Inc [CRBP] Stock bought by Insider Cormorant Asset Management, LP for $7.0 million – Knox Daily - Knox Daily
What is the investor’s view on Corbus Pharmaceuticals Holdings Inc (CRBP)? - US Post News
7 Best Russell 2000 Stocks to Buy According to Analysts - Insider Monkey
Wall Street SWOT: Corbus Pharmaceuticals stock shows promise amid clinical progress - Investing.com
325,140 Shares in Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) Acquired by Darwin Global Management Ltd. - Defense World
Corbus Pharmaceuticals Holdings Inc [NASDAQ: CRBP] Sees Increase in Stock Value - Knox Daily
Corbus Pharmaceuticals to Participate in the BMO Capital Markets' Oncology Summit - The Manila Times
Corbus Pharmaceuticals to Participate in the BMO Capital Markets’ Oncology Summit - GlobeNewswire
Corbus Pharmaceuticals Holdings Inc Stock (CRBP) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):